Arcus Biosciences (RCUS) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Pipeline and development strategy

• Focus on high-quality small molecule drug discovery, with casdatifan as the lead program for clear cell renal cell carcinoma and kidney cancer.

• Broad pipeline includes a late-stage pancreatic cancer trial with interim analysis expected in Q4, using a CD73 inhibitor.

• Early-stage immunology portfolio explores various inflammatory conditions.

Key clinical data and upcoming milestones

• October 20 event will present late-line monotherapy, second-line combination (casdatifan + cabozantinib), and frontline data.

• Second-line data aims to show a better hazard ratio for progression-free survival (PFS) compared to belzutifan, with a focus on real-world patient populations.

• Early overall survival (OS) curves for cas-cabo cohort will be shared, with late-line monotherapy showing promising PFS and potential OS benefit.

• Frontline data will include doublet (casdatifan + anti-PD-1) and triplet regimens, with low primary progression rates and favorable comparisons to ipi/nivo.

Differentiation and competitive positioning

• Casdatifan shows no efficacy deterioration with increased prior TKI exposure, unlike belzutifan.

• Combination with cabozantinib leverages physician preference and market share in second-line therapy.

• Frontline strategy targets improvement over ipi/nivo, which has a 30% market share but weaker PFS.

• Exploring TKI and PD-1 VEGF bispecific combinations, with three ongoing partnerships to maximize optionality and strategic value.